Beckman Coulter's Access Ostase
This article was originally published in The Gray Sheet
Executive Summary
Blood test is the first serum-based assay cleared by FDA as an aid in management of osteoporosis and Paget's disease, Beckman reports April 19. The automated assay can measure bone metabolism three to six months after osteoporosis therapy, while traditional bone densitometry can only measure changes after one to two years of therapy, the firm maintains